Sector News

Lilly appoints SVP of Corporate Affairs and Communications

May 10, 2017
Life sciences

Eli Lilly and Company announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017.

She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.

Pusey currently serves as president and CEO of the American Insurance Association (AIA), an insurance industry trade association representing more than 300 insurers that provide property and casualty insurance in the United States. She joined AIA in December 1996 and was promoted to president and CEO in February 2009. Pusey is consistently recognized by The Hill as one of the top lobbyists in Washington, D.C. and in 2012 she was named by National Journal as one of the 25 “Most Influential Women in Washington.”

“Leigh Ann brings a wealth of public affairs leadership experience to Lilly and at a particularly important time for our industry,” said Ricks. “Her ability to convene conversations and drive proactive policy solutions will be critical in our efforts to promote and sustain medical innovation so patients and the health care system benefit from a new era of medicine.”

Pusey serves in various capacities for a number of organizations, including as a member of the U.S. Chamber of Commerce’s Committee of 100, and board member of the Insurance Institute for Highway Safety. Prior to joining AIA, Pusey had been the deputy assistant to President George H.W. Bush for the White House Office of Public Liaison and deputy director of communications for the Republican National Committee. Pusey is a graduate of Samford University in Birmingham, Alabama. She currently resides in Alexandria, Virginia, with her husband and their two children.

Source: Eli Lilly and Company

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).